Siddhartha Sivaramakrishnan focuses his practice on the representation of APAC and EMEA investment bank underwriters, issuers and vendors in a wide range of US and international capital markets transactions. These include numerous equity and debt offerings under Rule 144A and Regulation S and SEC-registered offerings. Siddhartha also advises on M&A, de-SPAC and restructuring transactions.

Show More


  • Advised a Baltic gaming operator on its restructuring of its outstanding senior secured notes and related consent solicitation
  • Advised Kotak, Citi, Nomura and Haitong on the US$ 872 million IPO on the Bombay Stock Exchange and Rule 144A/Regulation S global offering of Gland Pharma, a leading generic injectables manufacturer majority owned by global pharmaceutical major Shanghai Fosun Pharma*
  • Advised Credit Suisse, Bank of America and UBS as joint sponsors on the US$ 1.31 billion SEC-registered global offering and secondary listing on the Hong Kong Stock Exchange of New Oriental Education and Technology, China’s largest private educational service provider*

Show More


  • Chambers Global 2022, Capital Markets: International, Singapore and International, India
  • Chambers Asia Pacific 2022, International Firms, India
  • Chambers Asia Pacific 2021-2022, Capital Markets: International, Singapore
  • Listed as an International A-List lawyer in India Business Law Journal, 2022
  • Legal 500 2021, Capital Markets: Equity And Debt: Foreign Firms
  • IFLR 1000 2021, Capital Markets Debt & Equity


Yale University
University of Oxford

England & Wales
New York